[go: up one dir, main page]

WO2017066943A1 - Procédé et kit pour l'assemblage in vitro de fragments d'adn - Google Patents

Procédé et kit pour l'assemblage in vitro de fragments d'adn Download PDF

Info

Publication number
WO2017066943A1
WO2017066943A1 PCT/CN2015/092438 CN2015092438W WO2017066943A1 WO 2017066943 A1 WO2017066943 A1 WO 2017066943A1 CN 2015092438 W CN2015092438 W CN 2015092438W WO 2017066943 A1 WO2017066943 A1 WO 2017066943A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
fragment
assembly
fragments
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/092438
Other languages
English (en)
Chinese (zh)
Inventor
陈泰
赵宏翠
范楚珧
陈世宏
王云
沈玥
徐讯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGI Shenzhen Co Ltd
Original Assignee
BGI Shenzhen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BGI Shenzhen Co Ltd filed Critical BGI Shenzhen Co Ltd
Priority to HK18113473.9A priority Critical patent/HK1254396B/xx
Priority to CN201580083695.7A priority patent/CN108138189B/zh
Priority to PCT/CN2015/092438 priority patent/WO2017066943A1/fr
Publication of WO2017066943A1 publication Critical patent/WO2017066943A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Definitions

  • the invention relates to the technical field of DNA assembly, and in particular to a method and a kit for assembling a DNA fragment in vitro.
  • DNA chemical synthesis methods can synthesize a certain length of DNA sequences from scratch, DNA synthesis of larger fragments must be completed by DNA assembly, so DNA assembly technology has become the most important basic experiment in the fields of synthetic biology and metabolic engineering.
  • DNA assembly technology has become the most important basic experiment in the fields of synthetic biology and metabolic engineering.
  • Another branch of the digestion and ligation method can assemble and link one or more linear or circular double-stranded DNA fragments to the assembled vector by enzymatic cleavage, ligation and simultaneous reaction. It is also a common assembly.
  • One of the methods there are still some insurmountable defects in the methods of digestion and ligation, such as restriction of restriction sites, number of fragments to be joined, and limitation of length.
  • the Gibson assembly method is especially convenient and has a wide range of applications.
  • a double-stranded linear DNA fragment carrying a homologous region can be assembled into a double-stranded linear DNA fragment by a one-step assembly reaction.
  • Gibson assembly also enables assembly and cloning of multiple single-stranded DNA fragments.
  • the Gibson assembly one-step splicing method has high synthesis cost and low splicing efficiency.
  • the present invention provides a method for in vitro assembly of DNA fragments which depends on overlapping sequences, and can assemble and clone a plurality of DNA fragments. Accordingly, the present invention also provides kits for in vitro assembly of DNA fragments.
  • the present invention provides a method for in vitro assembly of a DNA fragment, comprising the steps of assembling a plurality of DNA fragments and an assembly vector; wherein the plurality of DNA fragments are in a set fragment sequence, the first fragment The upstream and the last segment respectively have the same overlapping sequence as the above-mentioned assembled carrier, the other segments have the same overlapping sequence upstream of the previous segment, and the other segments have the same overlapping sequence upstream of the next segment;
  • the assembled vector comprises two overlapping sequences, optionally with an enzymatic cleavage site on its inner side, optionally with a screening marker between the cleavage sites; the above method allows the plurality of DNA fragments and the above-described assembled vector to be recognized
  • the endonuclease, exonuclease, DNA polymerase and DNA ligase of the above-mentioned cleavage site are brought into contact with each other, and the plurality of DNA fragments are assembled to the above-de
  • a kit for in vitro assembly of a DNA fragment comprising an assembly buffer and an assembly carrier; the kit for assembling a plurality of DNA fragments and an assembly carrier, wherein the above The DNA fragments are arranged in the same sequence of fragments, and the upstream of the first fragment and the downstream of the last fragment respectively have the same overlapping sequence as the above-mentioned assembled vector, and the other fragments have the same overlapping sequence upstream of the previous fragment, and other fragments.
  • the above-described assembled vector comprises two overlapping sequences, optionally with an enzyme cleavage site on its inner side, optionally with a screening marker between the cleavage sites;
  • the kit further comprises at least one of a positive control test fragment, an endonuclease, an exonuclease, a DNA polymerase, and a DNA ligase.
  • FIG. 1 is a schematic diagram showing the principle of assembly of a double-stranded circular DNA fragment according to an embodiment of the present invention
  • FIG. 2 is a schematic diagram showing the principle of assembling a mixed type DNA fragment according to an embodiment of the present invention
  • Figure 3 is a diagram showing the assembly test of a double-stranded circular DNA fragment according to an embodiment of the present invention
  • Figure 4 is a diagram showing the assembly of a double-stranded circular DNA fragment according to an embodiment of the present invention.
  • Figure 5 is a flat view of a mixed type DNA fragment assembly test according to an embodiment of the present invention.
  • Fig. 6 is a diagram showing the assembly of a mixed type DNA fragment and an enzyme digestion electrophoresis according to an embodiment of the present invention.
  • Embodiments of the present invention describe a method of in vitro assembly of DNA fragments that rely on overlapping sequences, which can be carried out in the same reaction system to complete assembly and cloning of multiple DNA fragments.
  • an embodiment of the present invention for a plurality of double-stranded DNA fragments cloned on a vector (i.e., fragment 1, fragment 2, and fragment 3, in other embodiments, the number of fragments may not be limited to three)
  • the set segment order ie, the order of segment 1, segment 2, and segment 3 in turn
  • the first segment (segment 1) upstream (01) and the last segment (segment 3) downstream (02) are respectively assembled and assembled
  • the same overlapping sequences (01 and 02) of the vector, the other fragments (segment 2) upstream (03) carry the same overlapping sequence as the downstream (03) of the previous fragment (segment 1), and the other fragments (fragment 2) are downstream (04) ) with the same overlapping sequence as the upstream (04) of the next segment (segment 3), with the overlapping sequences (01, 03, 04, 02) of each segment (segment 1, segment 2, and segment 3)
  • the cleavage site (E); the assembled vector has two
  • fragment and vector shown in Figure 1 are both intact double-stranded circular DNA structures and thus carry an enzyme cleavage site. If the fragment and vector are linear DNA fragments, there may be no restriction sites, and thus the restriction sites are "optionally", i.e., with or without restriction sites, as appropriate. Similarly, there may or may not be a screening marker on the vector, preferably a screening marker to increase screening efficiency.
  • the assembled carrier has two overlapping sequences (01 and 02), it should be understood that the method of the present invention does not limit that the assembled carrier can only include two overlapping sequences, but at least Two (such as three, four or more) overlapping sequences may be present, and other overlapping sequences may be located, for example, adjacent to the screening marker.
  • the above plurality of DNA fragments and the assembled vector are added to the reaction system, and a DNA endonuclease, an exonuclease, a DNA polymerase, and a DNA ligase which recognize the cleavage site (E) are simultaneously added.
  • the DNA endonuclease acts, and the DNA fragment and the assembled vector backbone to be assembled are excised from the plasmid (Fig. 1B), and then the DNA exonuclease acts to cleave the terminal overlapping region of the fragment and the assembled vector to reveal complementarity.
  • the cohesive ends, while the cohesive ends are complementary paired, the fragments to be assembled and the assembled vector are sequentially ligated into a loop (Fig.
  • the reaction product can be directly used for bacterial transformation such as Escherichia coli, and a monoclonal antibody is grown on the assembled vector resistant medium, the empty vector is removed by screening the label on the vector, the positive clone is picked, and the plasmid is obtained to obtain a large number of successfully assembled DNA. Fragment.
  • the method of the present invention is preferably in the assembly buffer of the same reaction system, the DNA fragment and the assembly vector are simultaneously combined with the endonuclease, exonuclease, and DNA polymerase which recognize the cleavage site.
  • the reaction with DNA ligase is carried out, that is, a one-step reaction is preferred; however, based on the spirit of the present invention, it can also be carried out stepwise, that is, the above-mentioned DNA endonuclease, exonuclease, DNA polymerase and DNA ligase are sequentially added to the reaction.
  • the reaction was carried out separately in the system.
  • the method of the present invention can be used not only for (a) assembly of double-stranded DNA fragments (i.e., double-stranded circular DNA fragments) which are both cloned on a vector, in which case, double-stranded DNA fragments are
  • double-stranded DNA fragments are The outer side of the overlapping sequence has a restriction site that can be recognized by the above DNA endonuclease; and can also be used for (b) assembly of double-stranded linear DNA fragments, and (c) assembly of single-stranded linear DNA fragments.
  • the number of single-stranded linear DNA fragments is even, and (d) any two or three types of DNA in a double-stranded DNA fragment, a double-stranded linear DNA fragment, and a single-stranded linear DNA fragment cloned on a vector a mixed assembly of fragments, in the presence of a double-stranded DNA fragment cloned on a vector, the outer side of the overlapping sequence on both sides of the double-stranded DNA fragment carries an enzyme cleavage site which is recognized by the above-mentioned DNA endonuclease;
  • the number of single-stranded linear DNA fragments is an even number. It is only necessary to have overlapping sequences as described above and as shown in FIG. The assembly principle is similar to the assembly of double-stranded circular DNA fragments.
  • efficient assembly can be achieved with overlapping sequences greater than 15 bp in length, preferably 20-40 bp.
  • the selection marker in the assembled vector can be any marker useful in bacteria, such as an antibiotic resistance gene, a fluorescent protein gene, a lethal gene, a lacZ gene, etc., or any combination thereof, A combination of a red fluorescent protein gene or a lacZ gene and a red fluorescent protein group gene is preferred.
  • the restriction site may be any restriction endonuclease recognition site or polyclonal restriction site (MCS), preferably a homeoendase (such as I-SceI) or a high density.
  • MCS polyclonal restriction site
  • Cloning sites eg, GGCCGCGGCGGCGC, GTCGACCGGACCGCGGGTC, GGGCCCGCCGGCGCGCC, CGCCGGCGCGCCGCCGCCGC, GACGACGTCGACCGCGGGTC, ACCGGACCGCGGGTCACC, GGCCGCCGGCGCC, etc.).
  • the cleavage site of the assembled fragment and the assembled vector requires that the cleavage site is not present on all of the assembled fragments and the assembled vector, and the cleavage sites may be the same or different. Since the reaction is carried out in the same system, and it is required that these cleavage sites must be present on all the assembled fragments and the assembled vector, otherwise the fragments or vectors are cleaved, so the same restriction sites are preferred. In order to reduce the risk of the assembled fragments and the assembled carrier being cut, and also simple and easy to operate, the requirements for the reaction system are also the simplest.
  • restriction enzymes can be used as the endonuclease of the present invention, and rare restriction enzymes with low probability of occurrence of cleavage sites, such as I-SceI, FseI, AscI, NotI, SfiI.
  • all double-stranded DNA exonucleases can be used in the present invention, preferably T5 exonuclease; all DNA polymerases can be used in the present invention, preferably DNA polymerases having 3'-exo-activity, such as phusion DNA polymerase, etc. All DNA ligases can be used in the present invention, preferably Taq DNA ligase.
  • the assembly vector only needs to have an overlapping sequence and an enzyme cleavage site, preferably the assembled vector described in the above embodiment of the invention.
  • the assembled vector is a linear DNA fragment, it may not have an enzyme cleavage site.
  • the invention can be used for the assembly of DNA fragments of any number and length.
  • double-stranded circular DNA fragments preferably used to assemble 1-20 DNA fragments larger than 200 bp
  • the total length of the fragments is less than 20 kbp
  • double-stranded linear DNA fragments it is preferably used to assemble 1-10 DNA fragments larger than 200 bp
  • the total length of the fragments is less than 20 kbp
  • single-stranded linear DNA fragments it is preferably used to assemble 2-20 (even) DNA fragments larger than 40 nt.
  • the total length is less than 1.5 kbp.
  • the preferred reaction conditions are 50 ° C reaction for 1 h. If some restriction enzymes have low enzymatic activity at 50 ° C, they can be reacted at their optimum temperature (such as 37 ° C) for 0.5-1 h, and then reacted at 50 ° C for 1 h.
  • the assembly buffer in one embodiment of the present invention contains Tris-acetic acid, magnesium ion, potassium ion, dNTPs, BSA (bovine serum albumin) and PEG 8000; preferably, the above assembly buffer further contains DTT (dithiothreitol), NAD + (nicotinamide adenine dinucleotide, coenzyme I); Change within a certain range.
  • the assembly buffer contains Tris-acetic acid 100 mmol/L, magnesium acetate 10 mmol/L, potassium acetate 20 mmol/L, dNTPs 0.2 mmol/L, DTT 10 mmol/L, NAD + 1 mmol/ L, BSA 100 ⁇ g/mL, PEG 8000 5% (mass/volume), pH 7.5.
  • the inventors have confirmed that the content of each of the above components varies within the range of 10% above and below the above value, and the pH is in the range of 7.2 to 7.8, and can be used as the assembly buffer of the present invention.
  • each component described above is an equal-magnification relationship (for example, 2, 3, 5, 6, or 8 times) in the upper and lower 10% range of the above numerical value
  • the pH may be in the range of 7.2 to 7.8, and may be configured as a mother liquid.
  • the assembly buffer is diluted in the corresponding multiples at the time of use to obtain an assembly buffer as a working solution.
  • a kit for in vitro assembly of DNA fragments comprising an assembly buffer and an assembly vector, optionally further comprising a positive control test fragment, an endonuclease, an exonuclease, a DNA polymerase, and At least one of DNA ligase; the kit is used to assemble a plurality of DNA fragments and an assembly vector, wherein the plurality of DNA fragments are respectively arranged in a sequence of fragments, upstream of the first fragment and downstream of the last fragment.
  • the other fragments are upstream with the same overlapping sequence as the downstream of the previous fragment, and the other fragments are downstream with the same overlapping sequence as the upstream of the next fragment;
  • the assembled vector comprises two overlapping sequences, optionally
  • the inside has an enzyme cleavage site.
  • a screening marker is placed between the cleavage sites of the above assembled vector.
  • the positive control test fragment described above has the same structural characteristics as the DNA fragment.
  • a kit may also be included in the specification, and the composition of the kit of the present invention and the method of use thereof may be described in the specification.
  • the assembly buffer and exonuclease (such as T5 DNA exo-cut)
  • the enzyme, DNA polymerase (such as Phusion DNA polymerase) and DNA ligase (such as Taq DNA ligase) are combined into an assembled master mix.
  • the user can carry out the assembly reaction by simply adding the DNA fragment to be assembled, the corresponding restriction enzyme and the assembly vector as required by the instructions.
  • the assembled vector may include a plasmid having at least one antibiotic resistance such as ampicillin (Amp), kanamycin (Kan), chloramphenicol (Cm), tetracycline (Tet), and spectinomycin (Spc).
  • the positive control test fragment can be a plurality (e.g., 3) of assembled test fragments (e.g., Saccharomyces cerevisiae synthetic sequence fragments) cloned on a vector (e.g., pMD18-T) to verify the effectiveness of the assembly system.
  • assembled test fragments e.g., Saccharomyces cerevisiae synthetic sequence fragments
  • vector e.g., pMD18-T
  • the DNA fragment in vitro assembly method described in the present invention can be used for gene synthesis, has few experimental steps, simple operation, and high success rate.
  • the synthesized single-stranded DNA fragments oligos
  • the synthesized single-stranded DNA fragments can be directly assembled into the target fragment by one-step reaction and simultaneously cloned into the assembled vector;
  • a plurality of circular plasmids carrying small DNA fragments are directly assembled into large DNA fragments by one-step assembly reaction, and simultaneously cloned into an assembly vector.
  • the DNA fragment in vitro assembly method described in the present invention can also be used for PCR product cloning and vector construction, has simple operation and high success rate, and is especially suitable for cloning and vector construction of multi-fragment, large-length PCR products.
  • the PCR product can be cloned into an assembled vector by a one-step assembly reaction by simply introducing an overlapping sequence on the primer.
  • the method of the present invention not only has a higher cloning success rate for smaller PCR products (e.g., below 2.5 kbp), but also for larger PCR products (e.g., 2.5 kbp-20 kbp).
  • the DNA fragment in vitro assembly method described in the present invention can also be used for metabolic pathway optimization. Since the ribosome binding site (RBS) and some promoter sequences are short (several to several tens of bp), conventional methods are difficult to manipulate, so the method of the present invention is particularly suitable for RBS optimization and simultaneous optimization of promoter and RBS. Simply add the corresponding overlapping sequence to both ends of the RBS or promoter to be optimized, and then synthesize it in the form of single-stranded DNA and mix it into the assembly reaction, and insert it into the metabolic pathway accurately by one-step assembly.
  • RBS ribosome binding site
  • the test DNA fragments were designated as TF101, TF102, TF103, TF104, TF105 and TF106, respectively.
  • the test fragments contained 20-40 bp homologous regions, and the upstream of TF101 and the downstream of TF106 each had a 40 bp overlapping sequence, and the restriction sites were BssHII.
  • the six fragments are the synthetic yeast chromosome 2 sequence, and the synthetic yeast chromosome 2 sequence information can be found in the patent application 201510008356.4.
  • the assembled vector carries the corresponding 40 bp overlapping sequence and the red fluorescent protein (mRFP1) screening marker, and the cleavage site is I-SceI.
  • the test fragment TF101 was amplified using the primers TF101-F and TF101-R listed in Table 1, and the test fragment TF102 was amplified using primers TF102-F and TF102-R, and the test fragment TF103 was amplified using primers TF103-F and TF103-R.
  • the test fragment TF104 was amplified using primers TF104-F, TF104-R, the test fragment TF105 was amplified using primers TF105-F, TF105-R, and the test fragment TF106 was amplified using primers TF106-F, TF106-R.
  • the TF101-TF105 template was a chunkC4 plasmid (sequence is SEQ ID NO: 1), and the TF106 template was chunkD4 (sequence is SEQ ID NO: 2).
  • the PCR reaction system was: 0.2 ⁇ L of ExTaq, 2 ⁇ L of 10 ⁇ ExTaq buffer, 1.6 ⁇ L of dNTPs, 1 ⁇ L of template DNA (2 ng/ ⁇ L), 1 ⁇ L of each of the positive and negative primers, and 13.2 ⁇ L of ddH 2 O.
  • the PCR reaction procedure was: 94 ° C for 5 min; 94 ° C for 30 sec, 55 ° C for 30 sec, 72 ° C for 1.5 min, 30 cycles; 72 ° C for 5 min.
  • the PCR product was purified using a PCR product purification kit.
  • PCR product was cloned into the pMD18-T vector using the TA cloning kit (TAKARA). Enzyme digestion was performed using the designed cleavage site. TF101, TF102, TF103, TF104, TF105 and TF106 plasmids were obtained, respectively.
  • TAKARA TA cloning kit
  • the red fluorescent protein gene was amplified using the primers RFP-F, RFP-R listed in Table 1, and the amplification template was pSB2K3: J04450 (from iGEM, www.igem.org, sequence is SEQ ID NO: 17).
  • the PCR reaction system was: 0.2 ⁇ L of Phusion DNA polymerase, 4 ⁇ L of 5 ⁇ HF buffer, 1.6 ⁇ L of dNTPs, 0.6 ⁇ L of MgCl 2 , 1 ⁇ L of template DNA (2 ng/ ⁇ L), 1 ⁇ L of positive and negative primers, and ddH 2 O 10.6 ⁇ L. .
  • the PCR reaction procedure was: 98 ° C 30 sec; 98 ° C 10 sec, 55 ° C 30 sec, 72 ° C 1 min, 35 cycles; 72 ° C 5 min.
  • the PCR product was purified using a PCR product purification kit.
  • the red fluorescent protein gene fragment and the pSBGAK vector were ligated by Gibson assembly to construct a group
  • the carrier is named pSBGAK-RFP.
  • the pSBGAK vector information and the Gibson assembly experimental method are described in Chinese Patent Application No. 201310085313.7.
  • the reaction system was prepared in a 1.5 mL centrifuge tube: 2 ⁇ L of assembly buffer, 0.25 ⁇ L of Phusion DNA polymerase, 1 ⁇ L of Taq DNA ligase, 0.8 ⁇ L of 1/100 T5 exonuclease, 1 ⁇ L of BssHII, and 0.5 ⁇ L of I-SceI. 280 ng of each of TF101, TF102, TF103, TF104, TF105, and TF106 plasmids, 28 ng of pSBGAK-RFP plasmid, and 20 ⁇ L of ddH 2 O. After reacting at 37 ° C for 30 min, the reaction was carried out at 50 ° C for 1 h.
  • E. coli DH5 ⁇ competent cells 50 ⁇ L of E. coli DH5 ⁇ competent cells were transformed by heat shock method using 10 ⁇ L of the assembly reaction solution, and plated with LB medium (containing kanamycin 50 ⁇ g/mL), and cultured at 37 ° C overnight.
  • Red and white clones were grown on the assembled transformation plates (Fig. 3), and 6 white clones (red clones were empty) were picked and inoculated into 3 mL of LB liquid medium (containing kanamycin 50 ⁇ g/mL). , shake at 37 ° C 200 rpm overnight.
  • plasmid small kit Tiangen Biochemical Technology (Beijing) Co., Ltd.
  • electrophoresis detection 2 ⁇ L of plasmid DNA plus 1 ⁇ L of 10 ⁇ loading buffer, mix and spot; 3 ⁇ L ⁇ -HindIII DNA Marker (TAKARA); 1.2% agarose gel, electrophoresis at 120 V for 40 min.
  • the plasmids of the six clones (lanes 1, 2, 3, 4, 5, 6) all met the expected size, and the results are shown in Fig. 4A.
  • the restriction endonucleases MluI (TAKARA) and XhoI (TAKARA) were used to identify the assembled plasmids.
  • the total length of the assembled plasmids was 11111 bp, and two bands were generated after digestion, and the sizes were 7679 bp and 3432 bp, respectively.
  • the digestion system was: MluI 0.3 ⁇ L, XhoI 0.3 ⁇ L, 10 ⁇ L buffer 1 ⁇ L, plasmid DNA 4 ⁇ L, and ddH 2 O 4.5 ⁇ L.
  • the enzyme was digested at 37 ° C for 1 h.
  • the results of electrophoresis detection were as follows: 1.1 ⁇ L of 10 ⁇ loading buffer was added to the digested product, 6 ⁇ L of the spot was taken, 3 ⁇ L of ⁇ -HindIII DNA Marker (TAKARA); 1.2% agarose gel, and electrophoresis at 120 V for 40 min.
  • the digestion bands of the six plasmids (lanes 1, 2, 3, 4, 5, 6) were all in line with the expected size, and the results are shown in Figure 4B.
  • the results of digestion of all white clones showed that the assembly accuracy of the six fragments was above 80%.
  • the green fluorescent protein (sfGFP) expression cassette assembly was taken as an example to demonstrate the feasibility of the method of the present invention for assembly of mixed-type DNA fragments.
  • the promoter and terminator are cloned on the pMD18-T vector,
  • the chain form exists, the restriction site is BssHII;
  • the RBS sequence exists as single-stranded linear DNA (oligo);
  • the green fluorescent protein gene fragment is a PCR product and exists as double-stranded linear DNA.
  • the cleavage site in the assembled vector is a high-density multiple cloning site, including SfiI, BsiWI, NgoMIV, PspOMI, EagI and other cleavage sites;
  • the screening marker is lacZ gene.
  • the promoters were amplified using the primers Promoter-F and Promoter-R listed in Table 2, and the terminator-F and terminator-R were used to amplify the terminator.
  • the template was pSB2K3: J04450 plasmid.
  • the PCR reaction system and procedure are the same as in Section 1.1.1 of the first embodiment except that the template and the primer are different.
  • the PCR product was purified using a PCR product purification kit.
  • the PCR product was cloned using the TA cloning kit (TAKARA). Promoter and terminator plasmids were obtained, respectively.
  • the RBS sequence is a mixture of four RBSs of different intensities, which are directly synthesized by a DNA synthesizer and purified by PAGE.
  • the RBS sequence is from iGEM (www.igem.org).
  • the four types of RBS information are shown in Table 3.
  • the green fluorescent protein was amplified using the primers GFP-F and GFP-R listed in Table 4, and the template was pUC19-5_emutS_CBM_3_GFP PCR (sequence is SEQ ID NO: 30).
  • the reaction system and procedure were the same except that the template and the primer were different. Section 1.2.
  • the PCR product was purified using a PCR product purification kit.
  • the lacZ was amplified using the primers lacZ-F, lacZ-R listed in Table 4, and the template was pUC19 (Promega).
  • the PCR reaction system and procedure are the same as in Section 1.2 of the first embodiment except that the template and the primer are different.
  • the lacZ was purified using a PCR product purification kit and ligated into the pSBGAK vector into an assembled vector designated pSBGAK-lacZ.
  • the assembly method is the same as the 1.2 in the first embodiment.
  • the reaction system was prepared in a 1.5 mL centrifuge tube: 10 ⁇ L of assembly buffer, 0.25 ⁇ L of Phusion DNA polymerase, 1 ⁇ L of Taq DNA ligase, 0.8 ⁇ L of 1/100 T5 exonuclease, 1 ⁇ L of BssHII, 0.5 ⁇ L of SfiI, promoter
  • the terminator plasmid was 150 ng each, the RBS fragment was 6.25 nM, the green fluorescent protein fragment was 35 ng, the assembled vector was 28 ng, and ddH 2 O was added to make up 20 ⁇ L.
  • the reaction was carried out at 50 ° C for 1 h.
  • E. coli DH5 ⁇ competent cells 50 ⁇ L of E. coli DH5 ⁇ competent cells were transformed by heat shock method using 10 ⁇ L of the assembly reaction solution, and plated with LB medium (containing kanamycin 50 ⁇ g/mL), and cultured at 37 ° C overnight.
  • plasmid small kit Tiangen Biochemical Technology (Beijing) Co., Ltd.
  • electrophoresis detection 2 ⁇ L of plasmid DNA plus 1 ⁇ L of 10 ⁇ loading buffer, mix and spot; 3 ⁇ L ⁇ -HindIII DNA Marker (TAKARA); 1.5% agarose gel, electrophoresis at 180V for 30 min.
  • the plasmids of the 19 clones all met the expected size, and the results are shown in Fig. 6A.
  • Two assembled plasmids were selected and identified by restriction endonuclease XhoI (TAKARA).
  • the total length of the assembled plasmid was 3245 bp, and three bands were generated after digestion, and the sizes were 1456 bp, 1026 bp and 763 bp, respectively.
  • the digestion system was: XhoI 0.5 ⁇ L, 1 ⁇ L of 10 ⁇ H buffer, 4 ⁇ L of plasmid DNA, and 4.5 ⁇ L of ddH 2 O.
  • the enzyme was digested at 37 ° C for 1 h.
  • Electrophoresis detection results Add 1.1 ⁇ L of 10 ⁇ loading buffer to the digested product, take 6 ⁇ L spot, 3 ⁇ L D2000 DNA Marker (Tiangen Biochemical Technology (Beijing) Co., Ltd.); 1.5% agarose gel, 180V The voltage was electrophoresed for 30 min. The enzymatic cleavage bands of the two plasmids all conformed to the expected size, and the results are shown in Fig. 6B.
  • RBS number The number of occurrences Frequency of occurrence BBa_B0034 2 10.5% BBa_B0030 6 31.6% BBa_B0032 7 36.8% BBa_B0031 4 21.1%
  • the assembly buffer of the present invention can be combined with an exonuclease (such as T5 exonuclease), a DNA polymerase (such as Phusion DNA polymerase), and a DNA ligase (such as Taq DNA ligase) into an assembled premix.
  • concentration of the assembly buffer may be N times (eg, 2, 3, 5, 8, or 10 times) of the working solution.
  • the preparation of the 3 ⁇ assembly buffer and the assembled premix in this example was as follows.
  • the plasmid DNA of the assembled vector and the test fragment was extracted using a plasmid extraction kit.
  • the assembled vector DNA concentration was adjusted to 28 ng/ ⁇ L; the test fragment DNA concentration was adjusted to 93 ng/ ⁇ L and stored at -20 °C.
  • Reaction component Amount added Assembly of premix 8.5 ⁇ L Endonuclease 1 ⁇ L Assembling DNA fragments * Assembly carrier 15ng
  • the formulation of 1 ⁇ assembly buffer was as follows: Tris-acetic acid (pH 7.5) 100 mmol/L, magnesium acetate 10 mmol/L, potassium acetate 20 mmol/L, dNTPs 0.2 mmol/L, DTT 10 mmol/L, NAD + 1 mmol/L, BSA 100 ⁇ g/mL, PEG 8000 5% (mass/volume).
  • each component may be varied within a range of 10% above and below the above value, and the pH is in the range of 7.2 to 7.8; or the content of each component is an equal ratio multiple of the upper and lower 10% of the above value, and the pH is Within the range of 7.2 to 7.8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé et un kit pour l'assemblage in vitro de fragments d'ADN, à même d'assembler une pluralité de fragments d'ADN avec un vecteur d'assemblage dans un ordre déterminé des fragments. L'amont du premier fragment et l'aval du dernier fragment portent respectivement une séquence chevauchante qui est identique au vecteur d'assemblage. En ce qui concerne les autres fragments, l'amont de chaque fragment porte une séquence chevauchante identique à l'aval du fragment précédent et l'aval de chaque fragment porte une séquence chevauchante identique à l'amont du fragment suivant. Le côté intérieur de la séquence chevauchante du vecteur d'assemblage porte respectivement, éventuellement, des sites de coupe par une enzyme de restriction et porte éventuellement des marqueurs sélectionnables entre les sites de coupe par une enzyme de restriction. Le procédé de la présente invention permet la réaction d'une pluralité de fragments d'ADN et du vecteur d'assemblage avec une ADN-endonucléase, une ADN-exonucléase, une ADN-polymérase et une ADN-ligase de manière à réaliser l'assemblage.
PCT/CN2015/092438 2015-10-21 2015-10-21 Procédé et kit pour l'assemblage in vitro de fragments d'adn Ceased WO2017066943A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HK18113473.9A HK1254396B (en) 2015-10-21 Method and kit for dna fragment assembling in vitro
CN201580083695.7A CN108138189B (zh) 2015-10-21 2015-10-21 一种dna片段体外组装方法和试剂盒
PCT/CN2015/092438 WO2017066943A1 (fr) 2015-10-21 2015-10-21 Procédé et kit pour l'assemblage in vitro de fragments d'adn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/092438 WO2017066943A1 (fr) 2015-10-21 2015-10-21 Procédé et kit pour l'assemblage in vitro de fragments d'adn

Publications (1)

Publication Number Publication Date
WO2017066943A1 true WO2017066943A1 (fr) 2017-04-27

Family

ID=58556628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/092438 Ceased WO2017066943A1 (fr) 2015-10-21 2015-10-21 Procédé et kit pour l'assemblage in vitro de fragments d'adn

Country Status (2)

Country Link
CN (1) CN108138189B (fr)
WO (1) WO2017066943A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110951759A (zh) * 2019-12-27 2020-04-03 苏州泓迅生物科技股份有限公司 一种超大质粒的体外组装方法及其应用
CN110964738A (zh) * 2019-12-27 2020-04-07 苏州泓迅生物科技股份有限公司 一种多片段dna组装试剂盒、多片段dna组装方法及其应用
CN110982834A (zh) * 2019-12-27 2020-04-10 苏州泓迅生物科技股份有限公司 一种质粒构建试剂盒、质粒构建方法及其应用
CN111004813A (zh) * 2019-12-27 2020-04-14 苏州泓迅生物科技股份有限公司 一种超大质粒构建试剂盒、超大质粒构建方法及其应用
CN112175939A (zh) * 2019-07-03 2021-01-05 华大青兰生物科技(无锡)有限公司 一种基于同源序列的核酸拼接方法及其应用
WO2021214258A1 (fr) 2020-04-22 2021-10-28 Fabmid Procédés de circularisation d'acides nucléiques linéaires double brin
US20220090090A1 (en) * 2019-01-15 2022-03-24 University Of Marlyland, Baltimore County A method for assembling circular and linear dna molecules in an ordered manner
CN114250242A (zh) * 2021-12-29 2022-03-29 上海英基生物科技有限公司 一种一步法BbsI酶切连接片段组装方法、组装试剂盒及应用
WO2023072958A1 (fr) 2021-10-25 2023-05-04 Fabmid Procédés de circularisation d'acides nucléiques linéaires double brin et leurs produits

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112011471B (zh) * 2019-05-31 2022-07-22 深圳华大生命科学研究院 酿制柠檬风味啤酒的酵母菌株、其制备方法及啤酒酿制方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101445807A (zh) * 2008-12-24 2009-06-03 宜春学院 一种新型高效的复杂载体构建的方法
CN102016070A (zh) * 2008-02-15 2011-04-13 合成基因组公司 体外连接和组合装配核酸分子的方法
US20120245100A1 (en) * 2011-03-22 2012-09-27 Brennan Winkler Plasmid for expression of transgenes in plants
CN104593354A (zh) * 2015-01-14 2015-05-06 江南大学 一种基于体外组合组装快速定向进化dna的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102016070A (zh) * 2008-02-15 2011-04-13 合成基因组公司 体外连接和组合装配核酸分子的方法
CN101445807A (zh) * 2008-12-24 2009-06-03 宜春学院 一种新型高效的复杂载体构建的方法
US20120245100A1 (en) * 2011-03-22 2012-09-27 Brennan Winkler Plasmid for expression of transgenes in plants
CN104593354A (zh) * 2015-01-14 2015-05-06 江南大学 一种基于体外组合组装快速定向进化dna的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JI, ZHICHENG ET AL.: "Application of Gibson Assembly Method for Plant Expression Vector Construction", JOURNAL OF SOUTH CHINA AGRICULTURAL UNIVERSITY, vol. 35, no. 5, 17 July 2014 (2014-07-17), pages 112 - 116, ISSN: 1001-411X *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220090090A1 (en) * 2019-01-15 2022-03-24 University Of Marlyland, Baltimore County A method for assembling circular and linear dna molecules in an ordered manner
CN112175939A (zh) * 2019-07-03 2021-01-05 华大青兰生物科技(无锡)有限公司 一种基于同源序列的核酸拼接方法及其应用
CN110951759A (zh) * 2019-12-27 2020-04-03 苏州泓迅生物科技股份有限公司 一种超大质粒的体外组装方法及其应用
CN110964738A (zh) * 2019-12-27 2020-04-07 苏州泓迅生物科技股份有限公司 一种多片段dna组装试剂盒、多片段dna组装方法及其应用
CN110982834A (zh) * 2019-12-27 2020-04-10 苏州泓迅生物科技股份有限公司 一种质粒构建试剂盒、质粒构建方法及其应用
CN111004813A (zh) * 2019-12-27 2020-04-14 苏州泓迅生物科技股份有限公司 一种超大质粒构建试剂盒、超大质粒构建方法及其应用
WO2021214258A1 (fr) 2020-04-22 2021-10-28 Fabmid Procédés de circularisation d'acides nucléiques linéaires double brin
WO2023072958A1 (fr) 2021-10-25 2023-05-04 Fabmid Procédés de circularisation d'acides nucléiques linéaires double brin et leurs produits
CN114250242A (zh) * 2021-12-29 2022-03-29 上海英基生物科技有限公司 一种一步法BbsI酶切连接片段组装方法、组装试剂盒及应用

Also Published As

Publication number Publication date
HK1254396A1 (zh) 2019-07-19
CN108138189A (zh) 2018-06-08
CN108138189B (zh) 2022-12-06

Similar Documents

Publication Publication Date Title
CN108138189B (zh) 一种dna片段体外组装方法和试剂盒
JP6594955B2 (ja) シントン形成
EP1692290B1 (fr) Plasmides de vecteur de clonage d'adn et leurs procedes d'utilisation
JP7106625B2 (ja) ゲノム大断片のダイレクトクローニングおよびｄｎａマルチ分子構築の新手法
EP2826862A1 (fr) Procédé de synthèse de gènes, puce à adn et kit
CN109022467A (zh) 新型多功能双荧光素酶报告基因质粒
US20230340481A1 (en) Systems and methods for transposing cargo nucleotide sequences
WO2019096054A1 (fr) Méthode de criblage d'une lignée cellulaire hek293 déficiente en glutamine synthétase
US20090176281A1 (en) Modular vector systems
Hopes et al. Genome editing in diatoms using CRISPR-Cas to induce precise bi-allelic deletions
Ortega et al. Overview of high-throughput cloning methods for the post-genomic era
CN107142247A (zh) 可诱导的CRISPRon或CRISPRi小鼠胚胎干细胞及其应用
Liang et al. Advanced eMAGE for highly efficient combinatorial editing of a stable genome
Jakočiūnas et al. Assembly and multiplex genome integration of metabolic pathways in yeast using CasEMBLR
CN102628057A (zh) 一种无背景定向克隆pcr产物的载体及制备方法和应用
JP7473953B2 (ja) 連結ｄｎａの製造方法及びそれに用いるためのベクターの組み合わせ
CN119998453A (zh) 用于大规模正交CRE介导的重组的新型LoxPsym位点
CN116004689A (zh) 一种清除双歧杆菌抗性质粒的基因编辑工具及其应用方法
Dong et al. CT5, a subtle in vitro DNA assembling method based on the combination of FnCas12a and T5 exonuclease
HK1254396B (en) Method and kit for dna fragment assembling in vitro
Kronbak et al. A novel approach to the generation of seamless constructs for plant transformation
CN108070610A (zh) 植物基因组定点敲入方法
Baek et al. Positive selection improves the efficiency of DNA assembly
Parui et al. Cloning and gene manipulation
CN102286515A (zh) 一种构建t载体的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15906461

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15906461

Country of ref document: EP

Kind code of ref document: A1